Hepatocellular carcinoma (HCC) remains one of the most common neoplasms worldwide. Curative treatment options include liver transplantation or resection. Unfortunately, most patients still have unresectable or untransplantable HCC due to disease extension or comorbid factors and are therefore candidate only for palliative treatments.
Methods
In this review we have analyzed the different medical approaches employed in the treatment of HCC in an attempt to better define their roles.
Results
Palliative medical treatments including systemic chemotherapy, immunotherapy or hormonal manipulation rarely influence survival of the patients. Although a high response rate is often reported with new local therapies such as transcatheter arterial embolization, intraarterial chemotherapy or percutaneous ethanol injection, the real impact of these treatment modalities on patient survival remains to be determined.
Conclusion
One way to improve the diagnosis of HCC patients would be an appropriate approach to evaluate new drugs or treatment modalities. To answer all the open questions, further trials, possibly randomized, should be conducted on a substantial number of patients with homogeneous prognostic factors.
Al-IdrissiH., IbrahimE., SatirA., SattiM., Al-KasemS., Al-OurainA.: Primary hepatocellular carcinoma in the Eastern Province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, adriamycin and mitomycin-C.Hepatogastroenterology, 32: 8–10, 1985.
2.
Al-JurfA., JochimsenP., ShiraziS., ZikeW., UrdanetaL.: Hepatic artery ligation and chemotherapeutic infusion in the treatment of hepatic malignancy.J. Surg. Oncol., 27: 119–123, 1984.
3.
Al-SarrafM., GotP., KithnerK., VaitkevieusV.: Primary liver cancer. A review of the clinical features, blood group, serum enzymes, therapy and survival of 65 cases.Cancer, 33: 574–582, 1974.
4.
AmreinP., RichardsF., ColemanM., PoulinR., HollandJ., WeinbergV., PerryM.: Phase II trial of amsacrine in patients with hepatoma: a Cancer and Leukemia Group B study.Cancer Treat. Rep., 68: 923–924, 1984.
5.
AndoK., HiraiK., KuboY.: Intra-arterial administration of epirubicin in the treatment of non-resectable hepatocellular carcinoma.Can. Chemother. Pharmacol., 19: 183–189, 1987.
6.
AnsfieldF., RamirezG., DavisH., WirtanenG., JohnsonR., BryanG., ManaloF., BordenF., DavisT., EsmailiM.: Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil.Cancer, 36: 2413–2417, 1975.
AudisioR.A., DociR., MazzaferroV., BellegottiT., TommasiniM., MontaltoF., MarchianòA., PivaA., De FazioC., DamasceniB., GennariL., van ThielD.H.: Hepatic arterial embolization with microencapsulated mitomycin C for unresectable hepatocellular carcinoma in cirrhosis.Cancer, 66: 228–236, 1990.
9.
BakerL.H., SaikiJ.H., JonesS.E., HewlettJ., BrownleeR., StephensR., VaitkeviciusV.: Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group Study.Cancer Treat. Rep., 61: 1595–1597, 1977.
10.
BannisterP.: Adrenoreceptors in hepatocellular carcinoma and liver.Gastroenterology, 90: 802–803, 1986.
11.
BeppuT., OharaC., YamaguchuY., SchiharaT., YamanakaT., KatafuchiS.: A new approach to chemoembolization for unresectable HCC using aclarubicin microspheres in combination with cisplatin suspended in iodized oil.Cancer, 68: 2555–2560, 1991.
12.
BernM., McDermottW., CadyB., OberfieldR., TreyC., ClouseM., TullisJ., ParkerL.: Intraarterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma - a clinical and pharmacology report.Cancer, 42: 399–405, 1978.
13.
BezwodaW.R., WeavingA., KewM.: Combination chemotherapy of hepatocellular cancer: comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM26 + 5-fluorouracil.Oncology, 44: 207–209, 1987.
14.
Bleiberg H., Grimaldi C.M., Gay F., Messner M., Rougier P.H., Kok T.C., EORTC Gastrointestinal Tract Cancer Cooperative Group: Double blind clinical trial of antiandrogen therapy versus placebo in unresectable hepatocellular carcinoma.Proc. Am. Soc. Clin. Oncol., 561, 1993.
15.
BakowskiR., LeghaS., SaikiJ., EyreH., O'BryanR.: Phase II trial of m-AMSA in hepatocellular carcinoma: a Southwest Oncology Group Study.Cancer Treat. Rep., 66: 1651–1652, 1982.
CarrB.I., IwatsukiS., BarovR., JainA., SelbeyR., MadariagaJ., BarnesJ.: Intrahepatic arterial cis-platinum and doxorubicin with or without lipiodol for advanced hepatocellular carcinoma (HCC): a prospective randomized study.Proc. Am. Soc. Clin. Oncol.,668, 1993.
18.
CavalliF., RozencweigM., RenardJ., GoldhirschA., HansenH.: Phase II study of oral VP-16-213 in hepatocellular carcinoma.Eur. J. Cancer Clin. Oncol., 17: 1079–1082, 1981.
19.
ChaoY., WuM.F., LiuJ.M., WangY.J., LeeS.D.: Treatment of hepatocellular carcinoma (HCC) with megace.Proc. Am. Soc. Clin. Oncol., 610, 1993.
ChenH., GrossJ.: Intra-arterial infusion of anticancer drugs: theoretical aspects of drug delivery and review of responses.Cancer Treat. Rep., 64: 31–40, 1980.
22.
ChengA.L., ChenY.C., SheuJ.C., ChenB.R., HsuH.C.: Chronic oral VP-16 plus tamoxifen in the treatment for advanced hepatocellular carcinoma.Proc. Am. Soc. Clin. Oncol.,605, 1993.
23.
ChengE., ChunH., SchiffC., KemenyN., SordilloP., YoungC.: Phase II trial and oral 4'demethoxydaunorubicin (DMDR) in patients (Pts) with primary liver carcinoma (PLC) (abstr.). Proc.Am. Soc. Clin. Oncol., 4: 88, 1985.
24.
ChengE., WatsonR., FortnerJ., KemenyN., GolbyR.: Regional intra-arterial infusion of cisplatin in primary liver cancer: a phase II trial (abstr). Proc.Am. Soc. Clin. Oncol., 2: 179, 1982.
ChlebowskiR., ChanK., TongM., WeinerJ., RydenV., BatemanJ., ChlebowskiJ.: Hepatocellular carcinoma - diagnostic and prognostic features in North American patients.Cancer, 53: 2701–2706, 1984.
27.
ChoiT., LeeN., WongJ.: Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy.Cancer, 53: 401–405, 1984.
28.
ColleoniM., BajettaE., NelliP., BoniL., BochicchioA.M., NolèF., BuzzoniR., CelioR., MazzaferroV., BonfantiG., BignamiP., GennariL.: Prognostic factors in patients affected by hepatocellular carcinoma treated with systemic chemotherapy: the experience of the National Cancer Institute of Milan.Ann. Oncol., 4: 489–493, 1993.
29.
ColleoniM., BuzzoniR., BajettaE., BochicchioA.M., BartoliC., AudisioR., BonfantiG., NolèF.: A phase II study of mitoxantrone and beta interferon in unresectable hepatocellular carcinoma.Cancer, 72: 3196–3201, 1993.
30.
ColleoniM., BajettaE., NolèF., NelliP., BozzettiF., BonfantiG., EboliM., RossettiC., CazzanigaM., Gallo StampinoC.: Doxifluridina associata ad acido folinico nel trattamento dei tumori del tratto epato-biliare (abstr).Tumori, 79: Suppl. 58, 1993.
31.
CollinsJ.: Pharmacologic rationale for regional drug delivery.J. Clin. Oncol., 2: 498–504, 1984.
32.
DamrongsakC., ViranuvattiV., ChearanaiO., TuchindaS.: Vinblastine in the treatment of carcinoma of the liver.J. Med. Assoc. Thailand, 56: 370–372, 1973.
33.
D'ArvilleC.N., JohnsonP.J.: Growth factors, endocrine aspects and hormonal treatment in hepatocellular carcinoma - an overview.J. Steroid Biochem. Mol. Biol., 37: 1007–1012, 1990.
34.
de BraudF., ColleoniM., NolèF., BajettaE.: Home therapy with interleukin-2 and beta-interferon in patients affected by colorectal and hepatocellular carcinoma.Oncology49: 472–476, 1994.
35.
DecarliA., La VecchiaC., NegriE., CislaghiC.: Cancer mortality in Italy, 1989, and an overview of trends from 1955 to 1989.Tumori, 79: 151–165, 1993.
van EedenV., FalksonG., BurgerW., AnsellS.M.: 5-Fluorouracil and leucovorin in hepatocellular carcinoma.Ann. Oncol., 3: 404–405, 1992.
38.
EngstromP.F., LevinB., MoertelC.G., SchuttA.: A phase II trial of tamoxifen in hepatocellular carcinoma.Cancer, 65: 2641–2643, 1990.
39.
FaganE.A., PulleyM., LimbA.: Adoptive immunotherapy administered via the hepatic artery and intralesional interleukin-2 in hepatocellular carcinoma.Cancer Treat. Rev.,16(A): 151–160, 1989.
40.
FalksonG., GoetzerB., KlassenD.: A phase II study of m-AMSA in patients with primary liver cancer.Cancer Chemother. Pharmacol., 6: 127–129, 1981.
41.
FalksonG., CoetzerB., TerblancheA.: Phase II trial of mitoxantrone in patients with primary liver cancer.Cancer Treat. Rep., 68: 1311–1312, 1984.
42.
FalksonG., MacIntyreJ., SchuttA., CoetzerB., JohnsonL., SimpsonI., DouglassH.: Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma.J. Clin. Oncol., 2: 581–584, 1984.
43.
FalksonG., MoertelC., LavinP., PretoriusF., CarboneP.: Chemotherapy studies in primary liver cancer - a prospective randomizer clinical trial.Cancer, 42: 2149–2156, 1978.
44.
FalksonG., Von HoffD., KlaassenD., PlessisH., Van der MerweC., Van der MerweA., CarboneP.: A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. An Eastern Cooperative Oncology Group pilot study.Cancer Chemother. Pharmacol., 4: 33–36, 1980.
45.
FalksonG., AnsellS.: Phase II trial of buserelin in hepatocellular carcinoma.Eur. J. Cancer Clin. Oncol., 25: 1339–1340, 1989.
46.
FalksonG., RyanL.M., JohnsonL.A., SimpsonW., CoeizerB.J., CarboneP.P., CreechR.H., AllanJ.S.: A randomized phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma.Cancer, 60: 2141–2145. 1987.
47.
FalksonG., CnaanA., SimpsonI., DayalY., FalksonH., SmithJ.J., MullerD.G.: A randomized phase II study of acivicin and 4′-deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group Study.Am. J. Clin. Oncol., 13: 510–515, 1990.
48.
FalksonG., MacIntyreJ., MoertelC., JohnsonL., ShermanR.: Primary liver cancer. An Eastern Cooperative Oncology Group Trial.Cancer, 54: 970–977, 1984.
49.
FarinatiF., SalvagniniM., de MariaN.: Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen.J. Hepatol., 11: 297–301, 1990.
50.
ForbesA., WilkinsonM.L., IqbalM.J., JohnsonP.J., WilliamsR.: Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5 alpha-dihydrotestosterone.Eur. J. Cancer Clin. Oncol., 23: 1659–1664, 1987.
51.
FriedmanM., DemanesD., HoffmanP.: Hepatomas hormone receptors and therapy.Am. J. Med., 73: 362–366, 1982.
52.
FriedmanM.A., VolberdingP., CassidyM., ResserK., WassermanT.; PhilipsT.: Therapy for hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil combined with whole-liver irradiation: a Northern California Oncology Group Study.Cancer Treat Rep., 63: 1885–1888, 1979.
53.
GailaniS., HollanJ.F., FalksonG.: Comparison of treatment of metastatic gastrointestinal cancer of fluorouracil (5-FU) to a combination of 5-FU with cytosine arabinoside.Cancer, 29: 1308–1313, 1972.
54.
Gastrointestinal Tumor Study Group: A prospective trial of recombinant human interferon alpha 2b in previously untreated patients with hepatocellular carcinoma.Cancer, 66: 135–139, 1990.
55.
GuptaS., KorulaJ.: Failure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinoma.J. Clin. Gastroenterol., 10: 651–654, 1988.
56.
HarveyW.H., FlemingT.R., BeltranG.: Phase II study of fludarabine phosphate in previously untreated patients with hepatoma: a Southwest Oncology Group Study.Cancer Treat. Rep., 71: 1111–1112, 1987.
57.
HendersonB.E., Preston-MartinS., EdmondsonH.A.: Hepatocellular carcinoma and oral contraceptives.Br. J. Cancer, 48: 437–440, 1983.
HohnD., StaggR., FriedmanM., IgnoffoR., RaynerA., HanniganJ., LewisB.: The NCOG randomized trial of intravenous (IV) vs hepatic arterial (IA) FUDR for colorectal cancer metastatic to the liver (abstr.). Proc.Am. Soc. Clin. Oncol., 6: 85, 1987.
60.
IhdeD., KaneR., CohenM., McIntireR., MinnaJ.: Adriamycin therapy in American patients with hepatocellular carcinoma.Cancer Treat. Rep., 61: 1385–1387, 1977.
61.
JohnsonP.J., KaayciC., DobbsN.: Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol.J. Hepatol., 13: 120–127, 1991.
62.
JonesV.D., PattY.Z., AjaniJ.A., AbbruzeseJ., CarrascoC.M., CharnsangavejC., LevinB.: A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatico to the liver.Cancer, 72: 2560–2563, 1993.
63.
KajantiM., PyrhoenS., MantylaM., RissanenP.: Intra-arterial and intravenous use of 4-epidoxorubicin combined with fluorouracil in primary hepatocellular carcinoma: a randomized comparison.Am. J. Clin. Oncol., 15: 37–40, 1992.
64.
KajantiM., RissanenP., VirkkunenP., FransillaR., MantylaM.: Regional intraarterial infusion of cisplatin in primary hepatocellular carcinoma.Cancer, 58: 2386–2388, 1986.
65.
KalaycíC., JohnsonP.J., DaviesS.E., WilliamsR.: Hepatitis B virus related hepatocellular carcinoma in the non-cirrhotic liver.J. Hepatol., 12: 54–59, 1991.
66.
KalaycíC., JohnsonP.J., RabyN.: Intraarterial adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin.J. Hepatol., 11: 349–353, 1990.
67.
KanematsuT., FurutaT., TakenataK., InokuchiK., TamuraJ.: A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma.Hepatology, 10: 89–102, 1989.
KasugaiH., KojimaJ., TatsutaM., OkudaJ., JasakiY.O., ImdokaS., FujitaM., IshiguroS.: Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil.Gastroenterology, 97: 965–971, 1989.
71.
KehayoglouK., AthanasiadesP., HartzoulakisI., PapavisiliaC.: A comparative study of the effect of adriamycin versus adriamycin-mitomicyn C on primary hepatocellular carcinoma (PHC). Excepta Med.Int. Congr. Ser., 484: 239–242, 1979.
KonnoK., MaedaH., IwaiK., TashiroS., MakiS., MorinagaT., MochinagaN., HiraokaT., YokoyamaI.: Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report.Eur. J. Cancer Clin. Oncol., 19: 1053–1065, 1983.
74.
KurodaC., SakurdiM., MoM.: Limitation of transcatheter arterial chemoembolization using iodized oil for small hepatocellular carcinoma.Cancer, 67: 81–86, 1991.
75.
LaiC.L., WuP.C., LokA.S.F., LinH.J., NiganH., LauJ., GhuugH.T., NgM.M.T., YeomE.K., ArnoldM.: Recombinant alpha 2 interferon is superior to doxorubicin on inoperable hepatocellular carcinoma: a prospective randomized trial.Br. J. Cancer, 60: 928–933, 1987.
76.
LaiC.L., WuP.C., ChanG.C.B., Juk-Fong, LinM.I.: Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma: a prospective randomized trial.Cancer, 62: 479–483, 1988.
77.
LaiE., ChoiT., TongS., OngG., WongJ.: Treatment of unresectable hepatocellular carcinoma: results of a randomized controlled trial.World J. Surg., 10: 501–509, 1986.
LaiK.H., TsaiY.T., LeeS.D., NgW.W., TengH.C., TamT.N., LogH., LinH.C., LinH.J., WuS.C., LayC.S., WangS.S., ChankW.K.: Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection.Cancer Chemother. Pharmacol., 23: 54–56, 1989.
80.
LemberskyB.C.: Implications of current therapeutic approaches in colorectal cancer for other gastrointestinal malignancies.Semin. Oncol., 18: 39–46, 1991.
81.
LinD.Y., LiawY.F., LeeT.Y., LaiC.M.: Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma - a randomized controlled trial.Gastroenterology, 94: 453–456, 1988.
82.
LinkJ., BatemanJ., ParolyW., DurkinW., PetersR.: 5-Fluorouracil in hepatocellular carcinoma - report of 21 cases.Cancer, 30: 1936–1939, 1973.
83.
LivraghiT., BolondiL., LazzaroniS., MariniG., MorabitoA., RapacciniG.L., SalmiA., TorzelliS.: Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis cancer.Cancer, 69: 925–929, 1992.
84.
MeliaW.M., JohnsonP.J., WilliamsR.: Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma.Cancer Treat. Rep., 71: 1213–1216, 1987.
85.
MeliaW.M., JohnsonP.J., WilliamsR.: Induction of remission in hepatocellular carcinoma: a comparison of VP-16 with adriamycin.Cancer, 51: 206–210, 1983.
86.
MeliaW., WestabyD., WilliamsR.: Diamminodichloride platinum (cis-platin) in the treatment of hepatocellular carcinoma.Clin. Oncol., 7: 275–280, 1981.
87.
MiazakiM., ShimodaT., HohH., KachoT., IinumaK., KojamaT., NakagawaK., AnddyK., AubiruS.: Enhancement of cytotoxicity of doxorubicin by verapamil in the hepatic artery infusion for liver tumours in rats.Cancer, 72: 349–354, 1993.
88.
MisraN., JaiswalM., SinghR., DasB.: Intrahepatic arterial infusion of the combination of mitomycin-C and 5-fluorouracil in treatment of primary and metastatic liver carcinoma.Cancer, 39: 1425–1429, 1977.
89.
MorstynG., IhdeD., EddyJ., BunnP., CohenM., MinnaJ.: Combination chemotherapy of hepatocellular carcinoma with doxorubicin and streptozotocin.Am. J. Clin. Oncol. (CCT), 6: 547–551, 1983.
90.
NagasueN., KohnoH., ChangY.C., MayashiT., UtsumiY., NakamuraT., YukayaH.: Androgen and estrogen receptors in hepatocellular carcinoma and the surrounding liver in women.Cancer, 63: 112–116, 1989.
91.
NairP., TongM., KempfR., CoR., LeeS.D., VenturiC.L.: Clinical, serologic and immunologic effects of human leukocyte interferon in HBsAG-positive primary hepatocellular carcinoma.Cancer, 56: 1018–1022, 1985.
92.
NerenstoneS.R., IhdeD.C., FriedmanM.A.: Clinical trials in primary hepatocellular carcinoma: current status and future directions.Cancer Treat. Rev., 15: 1–31, 1988.
93.
OhnishiK., TsuchivaS., NakayamaT., HiyamaY., IwanaS., GotoN., TabashiM., OhtsukiT., KonoK., NakajimaY., OkudaK.: Arterial chemoembolization of hepatocellular carcinoma with mitomycin C microcapsules.Radiology, 152: 51–55, 1984.
94.
OkudaK., OhtsukiT., ObataM., TonimatsuM., OkazakiN., MasegawaH., NakasimaY., OhnishiK.: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients.Cancer, 56: 918–928, 1985.
OlwenyC., Katongone-MbiddeE., BahendekaS., OtimD., MugerwaJ., KjalwaziS.: Further experience in treating patients with hepatocellular carcinoma in Uganda.Cancer, 46: 2712–2722, 1980.
97.
OlwenyC., ToyaT., Katongole-MbiddeE., MugerwaJ., KjalwaziS., CohenH.: Treatment of hepatocellular carcinoma with adriamycin - preliminary communications.Cancer, 36: 1250–1257, 1975.
98.
OnoharaS., KobayashiH., ItohY.: Intra-arterial cisplatinum infusion with sodium thiosulfate protection and angiotensin II-induced hypertension for treatment of hepatocellular carcinoma.Acta Radiol., 29: 197–202, 1988.
99.
OonC.: Clinical studies in Asian patients with irresectable primary hepatocellular carcinoma treated by adriamycin and prednisolone alone or in combination with 5-fluorouracil, vincristine and prednisone.Singapore Med. J., 19: 192–204, 1978.
100.
PattY., CharnsangavejC., LawrenceD., ChiangV., RichliR., CarrascoC.: Hepatic arterial infusion (HAI) of FUDR (F), leucovorin (L), adriamycin (A) and platimol P (FLAP): effective palliation for unresectable hepatocellular carcinoma (HCC).Proc. Am. Soc. Clin. Oncol., 474, 1992.
101.
PattY., CharnsangavejC., SaskiM.: Hepatic arterial infusion of floxuridine adriamycin and mitomycin-C for primary liver neoplasms.Dev. Oncol., 26: 125–140, 1984.
102.
PattY., NoonanC., PazdurR.: Phase II trial of 5-FU and r-interferon-alpha in hepatocellular carcinoma (HCC) (abstr.). Proc.ASCO10: 442, 1991.
103.
PattY., WallaceS., FreireichE., ChuangV., HershE., MavligitG.: The palliative role of hepatic arterial infusion and arterial occlusion in colorectal carcinoma metastatic to the liver.Lancet, 1: 349–351, 1981.
104.
PattY., YoffeB., CharnsangavejC., PazdurR., FischerH., ClearyK., RohM., SmithR., NoonanC., LevinB.: Low serum alpha-fetoprotein levels in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b.Cancer, 72: 2574–2582, 1993.
105.
PelletierG., RocheA., InkO.: A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.J. Hepatol., 77: 181–184, 1990.
106.
PettavelJ., MorgenthalerF.: Protracted arterial chemotherapy of liver tumors: an experience of 107 cases over a 12-year period.Prog. Clin. Cancer, 7: 217–233, 1978.
107.
RahmanA., TrecitJ., RohS.-K., PatkulL.A., AlvordW.G., ForstD., WooleyP.V.: A phase I clinical trial and pharmacokinetics: evaluation of liposome-encapsulated doxorubicin.Ann. Oncol., 8: 1093–1100, 1990.
108.
RathV., WillE., HanswaldV., KirstR.W., GalleP., OttoG., VolimM., KipperM., TrangottV., JohnsonP.J.: Doxorubicin plus verapamil as a multidrug resistance reverser in hepatocellular carcinoma.Proc. Am. Soc. Clin. Oncol., 696, 1993.
109.
RaveryM.J.R., OmuraG.A., BartolucciA.A.: Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: a Southeastern Cancer Study Group Trial.Cancer Treat. Rep., 70: 311–312, 1986.
110.
RaveryM.J.R., OmuraG.A., BartolucciA.A.: Phase II evaluation of epidoxorubicin plus bleomycin in hepatocellular carcinoma. A Southeastern Cancer Group trial.Cancer Treat. Rep., 68: 1517–1518, 1984.
111.
SachsE., Di BisceglieA.M., DushiekoG.M., JongE., LyonsS.F., ShoutsB.D., KewM.C.: Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study.Br. J. Cancer, 52: 105–109, 1985.
SasakiY., ImaokaS., KasugaiM., FusitaM., KawamotoS., IshiguroS.: A new approach to chemoembolization therapy for hepatoma using ethiodized oil cisplatin and gelatinum sponge.Cancer, 60: 1194–1203, 1987.
114.
SchewendenerR.A., FiebigH.H., BergerD.P.: Evaluation of incorporation characteristics of mitoxantrone into lamellar liposomas and analysis of the pharmacokinetic repertus, acute toxicity and antitumor efficacy.Cancer Chemother. Pharmacol., 27: 429–439, 1991.
115.
SekiT., NonakaY.: Ultrasonically guided percutaneous ethanol injection therapy for hepatocellular carcinoma.Am. J. Gastroenterol., 84: 1400–1407, 1989.
116.
ShepherdF.A., EvansW.K., BlacksteinM.E., FineS., HeathnoteS., LongerB., TaylorB., HabalF., KutasG., PritchardK., KuruvillaP.: Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma.J. Clin. Oncol., 5: 635–640, 1987.
117.
ShibataJ., FujiyamaS., SatoT., KdrumotoS., FukushimaS.: Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma.Cancer, 64: 1586–1594, 1989.
ShiraiM., WatanabeS., NishiokaM.: Antitumor effect of intratumoral injection of human recombinant interleukin-2 in patients with hepatocellular carcinoma: a preliminary report.Eur. J. Cancer, 26: 1045–1048, 1990.
120.
ShiuW., MokS.D., TsaoS.Y.: Phase II trial of epirubucin in hepatoma.Cancer Treat Rep., 70: 1035–1036, 1986.
121.
SonK., KewM., RabsonA.R.: Depressed natural killer cell activity in patients with hepatocellular carcinoma: in vitro effects of interferon and levamisole.Cancer, 50: 2880, 1982.
122.
StuartK., StokesK., JenkinsR., TreyC., ClouseM.: Treatment of HCC using doxorubicin/lipido/gelfoam.Cancer, 72: 320–329, 1993.
123.
TakayS.S., ShimaY., MuratnatsuY.: Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without a chemotherapeutic agent.Radiology, 162: 345–351, 1991.
124.
TaoM., LeungN., ShiuW., LeungW.T., LauY.W., LiA.K.C., ChanM., LaiY.S.: A phase II study of fluorouracil and high dose folinic acid in microcapsule hepatocellular carcinoma.Cancer Ther. Control., 2: 301–306, 1992.
VetterD., WengerJ.J., BergierJ.M., DofoelM., BockelR.: Transcatheter oily chemoenbolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western Comparative Study in 60 patients.Hepatology, 13: 427–433, 1991.
127.
WierrbickR., EirstA., ElwarithA., AjubI., KagenI.: Lack of activity of VP-16 in unresectable hepatocellular carcinoma (HCC) (abstr.).Proc. Am. Soc. Clin. Oncol.,534, 1992.
128.
YamashitaT., TakahashiM., KogaY.: Prognostic factors in the treatment of HCC with TAC and arterial infusion.Cancer, 67: 385–391, 1991.
129.
YoshidaT., OkazakiN., YoshinoM., OhkuraM., MiyamotoK., ShimadaY.: Phase II trial of mitoxantrone in patients with hepatocellular carcinoma.Eur. J. Cancer Clin. Oncol., 24: 1897–1898, 1988.
130.
YoshidaT., OkazakiN., YohnoM., OhkuraM.: Phase II trial of high dose recombinant gamma interferon in advanced HCC.Eur. J. Cancer, 26: 545–546, 1990.
